INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 169 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6,426,663 | +123.7% | 101,495 | +84.9% | 0.23% | +48.1% |
Q4 2021 | $2,873,000 | +212.6% | 54,885 | +122.7% | 0.16% | +243.5% |
Q3 2021 | $919,000 | -66.0% | 24,642 | -62.8% | 0.05% | -56.2% |
Q2 2021 | $2,704,000 | -38.7% | 66,232 | -49.1% | 0.10% | -26.1% |
Q1 2021 | $4,412,000 | -29.3% | 130,032 | -33.7% | 0.14% | -55.2% |
Q4 2020 | $6,237,000 | +116.0% | 196,126 | +74.3% | 0.32% | +77.1% |
Q2 2020 | $2,888,000 | +456.5% | 112,500 | +181.2% | 0.18% | +397.2% |
Q2 2019 | $519,000 | -59.0% | 40,000 | -61.5% | 0.04% | -49.3% |
Q1 2019 | $1,267,000 | -79.7% | 104,000 | -75.9% | 0.07% | -78.4% |
Q4 2017 | $6,253,000 | +42.3% | 431,874 | +55.1% | 0.33% | +48.4% |
Q3 2017 | $4,393,000 | +320.0% | 278,400 | +230.6% | 0.22% | +287.7% |
Q2 2017 | $1,046,000 | +37.3% | 84,200 | +68.4% | 0.06% | +29.5% |
Q3 2016 | $762,000 | – | 50,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |